{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:59:17Z","timestamp":1785463157327,"version":"3.56.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11682-4","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:48:55Z","timestamp":1785415735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A synergistic deep learning and machine learning framework for screening heterocyclic compounds against ALDH1A1"],"prefix":"10.1007","author":[{"given":"Shu-Chi","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-An","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monmi","family":"Pangging","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4947-1463","authenticated-orcid":false,"given":"Chung-Ta","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"11682_CR1","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.18632\/oncotarget.6920","volume":"7","author":"H Tomita","year":"2016","unstructured":"Tomita H, Tanaka K, Tanaka T, Hara A (2016) Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7:11018. https:\/\/doi.org\/10.18632\/oncotarget.6920","journal-title":"Oncotarget"},{"key":"11682_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/2051-5960-1-10","volume":"1","author":"C Bouvier","year":"2013","unstructured":"Bouvier C, Bertucci F, M\u00e9tellus P, Finetti P, de Paula AM, Forest F, Mokhtari K, Miquel C, Birnbaum D, Vasiljevic A (2013) ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study. Acta Neuropathol Commun 1:10. https:\/\/doi.org\/10.1186\/2051-5960-1-10","journal-title":"Acta Neuropathol Commun"},{"key":"11682_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3892\/ol.2025.14959","volume":"29","author":"L Varisli","year":"2025","unstructured":"Varisli L, Zoumpourlis P, Spandidos DA, Zoumpourlis V, Vlahopoulos S (2025) ALDH1A1 in breast cancer: a prospective target to overcome therapy resistance. Oncol Lett 29:213. https:\/\/doi.org\/10.3892\/ol.2025.14959","journal-title":"Oncol Lett"},{"key":"11682_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/labinvest.2009.127","volume":"90","author":"T Li","year":"2010","unstructured":"Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA, Jiang F (2010) ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients\u2019 outcome. Lab Invest 90:234\u2013244. https:\/\/doi.org\/10.1038\/labinvest.2009.127","journal-title":"Lab Invest"},{"key":"11682_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1254612","volume":"11","author":"K Lavudi","year":"2023","unstructured":"Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, Patnaik S, Kokkanti RR (2023) Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol 11:1254612. https:\/\/doi.org\/10.3389\/fcell.2023.1254612","journal-title":"Front Cell Dev Biol"},{"key":"11682_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107781","volume":"216","author":"A Farahani","year":"2025","unstructured":"Farahani A, Farahani A, Kashfi K, Ghasemi A (2025) Inducible nitric oxide synthase (iNOS): more than an inducible enzyme? Rethinking the classification of NOS isoforms. Pharmacol Res 216:107781. https:\/\/doi.org\/10.1016\/j.phrs.2025.107781","journal-title":"Pharmacol Res"},{"key":"11682_CR7","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/modpathol.2011.172","volume":"25","author":"T Khoury","year":"2012","unstructured":"Khoury T, Ademuyiwa FO, Chandraseekhar R, Jabbour M, DeLeo A, Ferrone S, Wang Y, Wang X (2012) Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol 25:388\u2013397. https:\/\/doi.org\/10.1038\/modpathol.2011.172","journal-title":"Mod Pathol"},{"key":"11682_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13024-019-0332-6","volume":"14","author":"A Masato","year":"2019","unstructured":"Masato A, Plotegher N, Boassa D, Bubacco L (2019) Impaired dopamine metabolism in Parkinson\u2019s disease pathogenesis. Mol Neurodegener 14:35. https:\/\/doi.org\/10.1186\/s13024-019-0332-6","journal-title":"Mol Neurodegener"},{"key":"11682_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbi.2014.10.028","volume":"234","author":"CA Morgan","year":"2015","unstructured":"Morgan CA, Hurley TD (2015) Development of a high-throughput in vitro assay to identify selective inhibitors for human ALDH1A1. Chem-Biol Interact 234:29\u201337. https:\/\/doi.org\/10.1016\/j.cbi.2014.10.028","journal-title":"Chem-Biol Interact"},{"key":"11682_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.659550","volume":"8","author":"K Shortall","year":"2021","unstructured":"Shortall K, Djeghader A, Magner E, Soulimane T (2021) Insights into aldehyde dehydrogenase enzymes: a structural perspective. Front Mol Biosci 8:659550. https:\/\/doi.org\/10.3389\/fmolb.2021.659550","journal-title":"Front Mol Biosci"},{"key":"11682_CR11","doi-asserted-by":"publisher","first-page":"921","DOI":"10.7150\/ijbs.42300","volume":"16","author":"W Wang","year":"2020","unstructured":"Wang W, Wang C, Xu H, Gao Y (2020) Aldehyde dehydrogenase, liver disease and cancer. Int J Biol Sci 16:921. https:\/\/doi.org\/10.7150\/ijbs.42300","journal-title":"Int J Biol Sci"},{"key":"11682_CR12","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1021\/jm501900s","volume":"58","author":"CA Morgan","year":"2015","unstructured":"Morgan CA, Hurley TD (2015) Characterization of two distinct structural classes of selective aldehyde dehydrogenase 1A1 inhibitors. J Med Chem 58:1964\u20131975. https:\/\/doi.org\/10.1021\/jm501900s","journal-title":"J Med Chem"},{"key":"11682_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29204810","volume":"29","author":"J Jampilek","year":"2024","unstructured":"Jampilek J (2024) Heterocycles in medicinal chemistry II. Molecules 29:4810. https:\/\/doi.org\/10.3390\/molecules29204810","journal-title":"Molecules"},{"key":"11682_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cplett.2026.142680","author":"R B\u00e1ez-Grez","year":"2026","unstructured":"B\u00e1ez-Grez R, Pino-Rios R (2026) Revisiting aromaticity of five-membered rings: a dissected ring current analysis. Chem Phys Lett. https:\/\/doi.org\/10.1016\/j.cplett.2026.142680","journal-title":"Chem Phys Lett"},{"key":"11682_CR15","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.1039\/d5md00403a","volume":"16","author":"M Ward","year":"2025","unstructured":"Ward M, O\u2019Boyle NM (2025) Analysis of the structural diversity of heterocycles amongst European medicines agency approved pharmaceuticals (2014\u20132023). RSC Med Chem 16:4540\u20134570. https:\/\/doi.org\/10.1039\/d5md00403a","journal-title":"RSC Med Chem"},{"key":"11682_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.proci.2024.105675","volume":"40","author":"B Chen","year":"2024","unstructured":"Chen B, Lyu H, Liu P, Samaras VG, Lu X, Gao X, Roberts WL, Pitsch H (2024) On the formation of pyridine, the first nitrogen heterocyclic ring in NPAHs. Proc Combust Inst 40:105675. https:\/\/doi.org\/10.1016\/j.proci.2024.105675","journal-title":"Proc Combust Inst"},{"key":"11682_CR17","doi-asserted-by":"publisher","first-page":"11622","DOI":"10.1021\/acs.jmedchem.4c01122","volume":"67","author":"CM Marshall","year":"2024","unstructured":"Marshall CM, Federice JG, Bell CN, Cox PB, Njardarson JT (2024) An update on the nitrogen heterocycle compositions and properties of US FDA-approved pharmaceuticals (2013\u20132023). J Med Chem 67:11622\u201311655. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c01122","journal-title":"J Med Chem"},{"key":"11682_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","volume":"30","author":"LB Kilburn","year":"2024","unstructured":"Kilburn LB, Khuong-Quang D-A, Hansford JR, Landi D, van Der Lugt J, Leary SE, Driever PH, Bailey S, Perreault S, McCowage G (2024) The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med 30:207\u2013217. https:\/\/doi.org\/10.1038\/s41591-023-02668-y","journal-title":"Nat Med"},{"key":"11682_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104634","volume":"299","author":"E Tkacik","year":"2023","unstructured":"Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ (2023) Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. J Biol Chem 299:104634. https:\/\/doi.org\/10.1016\/j.jbc.2023.104634","journal-title":"J Biol Chem"},{"key":"11682_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111285","volume":"137","author":"C Sethy","year":"2021","unstructured":"Sethy C, Kundu CN (2021) 5-Fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition. Biomed Pharmacother 137:111285. https:\/\/doi.org\/10.1016\/j.biopha.2021.111285","journal-title":"Biomed Pharmacother"},{"key":"11682_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106324","volume":"181","author":"D Vemula","year":"2023","unstructured":"Vemula D, Jayasurya P, Sushmitha V, Kumar YN, Bhandari V (2023) CADD, AI and ML in drug discovery: a comprehensive review. Eur J Pharm Sci 181:106324. https:\/\/doi.org\/10.1016\/j.ejps.2022.106324","journal-title":"Eur J Pharm Sci"},{"key":"11682_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-021-00522-2","volume":"13","author":"AT McNutt","year":"2021","unstructured":"McNutt AT, Francoeur P, Aggarwal R, Masuda T, Meli R, Ragoza M, Sunseri J, Koes DR (2021) GNINA 1.0: molecular docking with deep learning. J Cheminform 13:43. https:\/\/doi.org\/10.1186\/s13321-021-00522-2","journal-title":"J Cheminform"},{"key":"11682_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13321-025-00973-x","volume":"17","author":"AT McNutt","year":"2025","unstructured":"McNutt AT, Li Y, Meli R, Aggarwal R, Koes DR (2025) GNINA 1.3: the next increment in molecular docking with deep learning. J Cheminform 17:28. https:\/\/doi.org\/10.1186\/s13321-025-00973-x","journal-title":"J Cheminform"},{"key":"11682_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1039\/d2va00182a","volume":"2","author":"Y Gou","year":"2023","unstructured":"Gou Y, Shen L, Cui S, Huang M, Wu Y, Li P, Zhuang S (2023) Machine learning based models for high-throughput classification of human pregnane X receptor activators. Environ Sci Adv 2:304\u2013312. https:\/\/doi.org\/10.1039\/d2va00182a","journal-title":"Environ Sci Adv"},{"key":"11682_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/17425255.2021.1865309","volume":"17","author":"S Pathania","year":"2021","unstructured":"Pathania S, Singh PK (2021) Analyzing FDA-approved drugs for compliance of pharmacokinetic principles: should there be a critical screening parameter in drug designing protocols? Expert Opin Drug Metab Toxicol 17:351\u2013354. https:\/\/doi.org\/10.1080\/17425255.2021.1865309","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"11682_CR26","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.15115844","author":"G Landrum","year":"2025","unstructured":"Landrum G, Tosco P, Kelley B, Rodriguez R, Cosgrove D, Vianello R, Gedeck P, Jones G, Kawashima E, Nealschneider D (2025) rdkit\/rdkit: 2025_03_1 (Q1 2025) Release. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.15115844"},{"key":"11682_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13321-019-0336-9","volume":"11","author":"PJ Ropp","year":"2019","unstructured":"Ropp PJ, Kaminsky JC, Yablonski S, Durrant JD (2019) Dimorphite-DL: an open-source program for enumerating the ionization states of drug-like small molecules. J Cheminform 11:14. https:\/\/doi.org\/10.1186\/s13321-019-0336-9","journal-title":"J Cheminform"},{"key":"11682_CR28","doi-asserted-by":"publisher","first-page":"13045","DOI":"10.1021\/acs.jcim.5c02271","volume":"65","author":"D Santos-Martins","year":"2025","unstructured":"Santos-Martins D, He Y, Eberhardt J, Sharma P, Bruciaferri N, Holcomb M, Llanos MA, Hansel-Harris A, Barkdull AP, Tillack AF (2025) Meeko: molecule parametrization and software interoperability for docking and beyond. J Chem Inf Model 65:13045\u201313050. https:\/\/doi.org\/10.1021\/acs.jcim.5c02271","journal-title":"J Chem Inf Model"},{"key":"11682_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4236\/mri.2019.83003","volume":"8","author":"S Hossain","year":"2019","unstructured":"Hossain S, Sarkar B, Prottoy MNI, Araf Y, Taniya MA, Ullah MA (2019) Thrombolytic activity, drug likeness property and ADME\/T analysis of isolated phytochemicals from ginger (Zingiber officinale) using in silico approaches. Mod Res Inflamm 8:29\u201343. https:\/\/doi.org\/10.4236\/mri.2019.83003","journal-title":"Mod Res Inflamm"},{"key":"11682_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4236\/aer.2021.94006","volume":"9","author":"A Carrasco-Carballo","year":"2021","unstructured":"Carrasco-Carballo A, Mar\u00edn-Merino E, Merino-Montiel P, Colin-Lozano B, Hilerio SLC, Hilario-Mart\u00ednez JC, Sandoval-Ram\u00edrez J (2021) Steroidal plant growth promoters vs. phytopathogens, via enzymatic regulation; an in silico approach. Adv Enzyme Res 9:55\u201371. https:\/\/doi.org\/10.4236\/aer.2021.94006","journal-title":"Adv Enzyme Res"},{"key":"11682_CR31","doi-asserted-by":"publisher","first-page":"9388","DOI":"10.1021\/acs.jcim.4c01429","volume":"64","author":"I Dunn","year":"2024","unstructured":"Dunn I, Pirhadi S, Wang Y, Ravindran S, Concepcion C, Koes DR (2024) CACHE challenge #1: docking with GNINA is all you need. J Chem Inf Model 64:9388\u20139396. https:\/\/doi.org\/10.1021\/acs.jcim.4c01429","journal-title":"J Chem Inf Model"},{"key":"11682_CR32","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1021\/jm020155c","volume":"45","author":"YC Martin","year":"2002","unstructured":"Martin YC, Kofron JL, Traphagen LM (2002) Do structurally similar molecules have similar biological activity? J Med Chem 45:4350\u20134358. https:\/\/doi.org\/10.1021\/jm020155c","journal-title":"J Med Chem"},{"key":"11682_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.1298","volume":"7","author":"S Yuan","year":"2017","unstructured":"Yuan S, Chan HS, Hu Z (2017) Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci 7:e1298. https:\/\/doi.org\/10.1002\/wcms.1298","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"11682_CR34","doi-asserted-by":"publisher","DOI":"10.1063\/1.4818885","author":"D Prada-Gracia","year":"2013","unstructured":"Prada-Gracia D, Shevchuk R, Rao F (2013) The quest for self-consistency in hydrogen bond definitions. J Chem Phys. https:\/\/doi.org\/10.1063\/1.4818885","journal-title":"J Chem Phys"},{"key":"11682_CR35","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E (2021) Gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 17:6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Comput"},{"key":"11682_CR36","doi-asserted-by":"publisher","first-page":"12959","DOI":"10.1021\/acs.jcim.5c02352","volume":"65","author":"L Almena Rodriguez","year":"2025","unstructured":"Almena Rodriguez L, Spanke VA, Kersten C (2025) Solvent-site prediction for fragment docking and its implication on fragment-based drug discovery. J Chem Inf Model 65:12959\u201312977. https:\/\/doi.org\/10.1021\/acs.jcim.5c02352","journal-title":"J Chem Inf Model"},{"key":"11682_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge I (2003) Selection criteria for drug\u2010like compounds. Med Res Rev 23:302\u2013321. https:\/\/doi.org\/10.1002\/med.10041","journal-title":"Med Res Rev"},{"key":"11682_CR38","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1021\/acschembio.7b00685","volume":"13","author":"Y Chen","year":"2017","unstructured":"Chen Y, Zhu J-Y, Hong KH, Mikles DC, Georg GI, Goldstein AS, Amory JK, Schonbrunn E (2017) Structural basis of ALDH1A2 inhibition by irreversible and reversible small molecule inhibitors. ACS Chem Biol 13:582\u2013590. https:\/\/doi.org\/10.1021\/acschembio.7b00685","journal-title":"ACS Chem Biol"},{"key":"11682_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000011923","volume":"56","author":"C Kollmannsberger","year":"1999","unstructured":"Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan\u2013a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1\u201312. https:\/\/doi.org\/10.1159\/000011923","journal-title":"Oncology"},{"key":"11682_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/s1470-2045(16)00106-6","volume":"17","author":"IE Krop","year":"2016","unstructured":"Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC (2016) Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 17:811\u2013821. https:\/\/doi.org\/10.1016\/s1470-2045(16)00106-6","journal-title":"Lancet Oncol"},{"key":"11682_CR41","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1021\/ci700157b","volume":"47","author":"C R\u00fccker","year":"2007","unstructured":"R\u00fccker C, R\u00fccker G, Meringer M (2007) Y-Randomization and its variants in QSPR\/QSAR. J Chem Inf Model 47:2345\u20132357. https:\/\/doi.org\/10.1021\/ci700157b","journal-title":"J Chem Inf Model"},{"key":"11682_CR42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1021\/jp506376z","volume":"119","author":"N Deng","year":"2015","unstructured":"Deng N, Forli S, He P, Perryman A, Wickstrom L, Vijayan R, Tiefenbrunn T, Stout D, Gallicchio E, Olson AJ (2015) Distinguishing binders from false positives by free energy calculations: fragment screening against the flap site of HIV protease. J Phys Chem B 119:976\u2013988. https:\/\/doi.org\/10.1021\/jp506376z","journal-title":"J Phys Chem B"},{"key":"11682_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1161\/hypertensionaha.120.15352","volume":"77","author":"E Pinilla","year":"2021","unstructured":"Pinilla E, Comerma-Steffensen S, Prat-Duran J, Rivera L, Matchkov VV, Buus NH, Simonsen U (2021) Transglutaminase 2 inhibitor LDN 27219 age-dependently lowers blood pressure and improves endothelium-dependent vasodilation in resistance arteries. Hypertension 77:216\u2013227. https:\/\/doi.org\/10.1161\/hypertensionaha.120.15352","journal-title":"Hypertension"},{"key":"11682_CR44","doi-asserted-by":"publisher","first-page":"9534","DOI":"10.1021\/acs.jmedchem.8b00855","volume":"61","author":"AH Hansen","year":"2018","unstructured":"Hansen AH, Sergeev E, Bolognini D, Sprenger RR, Ekberg JH, Ejsing CS, McKenzie CJ, Rexen Ulven E, Milligan G, Ulven T (2018) Discovery of a potent thiazolidine free fatty acid receptor 2 agonist with favorable pharmacokinetic properties. J Med Chem 61:9534\u20139550. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00855","journal-title":"J Med Chem"},{"key":"11682_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s44371-025-00130-1","volume":"2","author":"BT Ogunyemi","year":"2025","unstructured":"Ogunyemi BT, Abdul-Hammed M, Adedotun IO, Egunjobi BT, Badmos ST, Adegboyega TA, Aderogba AA, Adeosun GG (2025) Protein\u2013ligand molecular dynamics simulation (PL-MDS), ADMET analyses, and bioactivity studies of phytochemicals from Aloe vera: an in-silico novel antidiabetics drug discovery effort. Discov chem 2:55. https:\/\/doi.org\/10.1007\/s44371-025-00130-1","journal-title":"Discov chem"},{"key":"11682_CR46","doi-asserted-by":"publisher","first-page":"11430","DOI":"10.1021\/acs.jpcb.5c05390","volume":"129","author":"M Schaffler","year":"2025","unstructured":"Schaffler M, Wales DJ, Strodel B (2025) Energy landscape and kinetic analysis of molecular dynamics simulations for intrinsically disordered proteins. J Phys Chem B 129:11430\u201311440. https:\/\/doi.org\/10.1021\/acs.jpcb.5c05390","journal-title":"J Phys Chem B"},{"key":"11682_CR47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden S, Ryde U (2015) The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov 10:449\u2013461. https:\/\/doi.org\/10.1517\/17460441.2015.1032936","journal-title":"Expert Opin Drug Discov"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11682-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11682-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:24:54Z","timestamp":1785461094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11682-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":47,"alternative-id":["11682"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11682-4","relation":{"references":[{"id-type":"doi","id":"10.5281\/zenodo.15115844","asserted-by":"subject"}]},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript does not contain data collected from humans or animals.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have reviewed and approved the manuscript for publication.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}